{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:10:11Z","timestamp":1789657811615,"version":"4.0.1"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.126.272415","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:51:04Z","timestamp":1783003864000},"page":"1440-1447","source":"Crossref","is-referenced-by-count":0,"title":["Overall Survival with [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617 Versus [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA I&amp;T: A Propensity Score\u2013Matched Real-World Analysis"],"prefix":"10.2967","volume":"67","author":[{"given":"Natalie","family":"Hasenauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Schloetelburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Jedamzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026091707501255000_67.9.1440.1","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501255000_67.9.1440.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091707501255000_67.9.1440.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026091707501255000_67.9.1440.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026091707501255000_67.9.1440.5","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501255000_67.9.1440.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191023"},{"key":"2026091707501255000_67.9.1440.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091707501255000_67.9.1440.8","doi-asserted-by":"crossref","first-page":"835956","DOI":"10.3389\/fonc.2022.835956","article-title":"177Lu-PSMA-I&t radioligand therapy for treating metastatic castration-resistant prostate cancer: a single-centre study in east Asians","volume":"12","author":"Bu","year":"2022","journal-title":"Front Oncol."},{"key":"2026091707501255000_67.9.1440.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550"},{"key":"2026091707501255000_67.9.1440.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147413"},{"key":"2026091707501255000_67.9.1440.11","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (SPLASH) [abstract]","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol."},{"key":"2026091707501255000_67.9.1440.12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/jcm9051390","article-title":"Metabolic tumour volume from PSMA PET\/CT scans of prostate cancer patients during chemotherapy\u2014do different software solutions deliver comparable results?","volume":"9","author":"Hartrampf","year":"2020","journal-title":"J Clin Med."},{"key":"2026091707501255000_67.9.1440.13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ph10040077","article-title":"Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer","volume":"10","author":"Cardinale","year":"2017","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026091707501255000_67.9.1440.14","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3993"},{"key":"2026091707501255000_67.9.1440.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266702"},{"key":"2026091707501255000_67.9.1440.16","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"2026091707501255000_67.9.1440.17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026091707501255000_67.9.1440.18","unstructured":"Common terminology criteria for adverse events (CTCAE) version 6.0. National Cancer Institute website. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf. Published July 22, 2025. Accessed May 3, 2026."},{"key":"2026091707501255000_67.9.1440.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270170"},{"key":"2026091707501255000_67.9.1440.20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-024-01143-0","article-title":"Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval","volume":"14","author":"Karimzadeh","year":"2024","journal-title":"EJNMMI Res."},{"key":"2026091707501255000_67.9.1440.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2026091707501255000_67.9.1440.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264964"},{"key":"2026091707501255000_67.9.1440.23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/pros.23878","article-title":"Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer","volume":"79","author":"Wang","year":"2019","journal-title":"Prostate."},{"key":"2026091707501255000_67.9.1440.24","doi-asserted-by":"crossref","first-page":"e14014","DOI":"10.1111\/eci.14014","article-title":"Prognostic role of early prostate specific antigen changes after [177Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: a meta-analysis","volume":"53","author":"Giovanella","year":"2023","journal-title":"Eur J Clin Invest."},{"key":"2026091707501255000_67.9.1440.25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617","volume":"44","author":"Ahmadzadehfar","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091707501255000_67.9.1440.26","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget."},{"key":"2026091707501255000_67.9.1440.27","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1043026"},{"key":"2026091707501255000_67.9.1440.28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2026091707501255000_67.9.1440.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3696"},{"key":"2026091707501255000_67.9.1440.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452"},{"key":"2026091707501255000_67.9.1440.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264293"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:51:42Z","timestamp":1789656702000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.126.272415"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272415","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}